CN115701995A - 用于治疗皮肤红斑狼疮的tlr7抑制剂与泼尼松龙或羟氯喹的组合 - Google Patents

用于治疗皮肤红斑狼疮的tlr7抑制剂与泼尼松龙或羟氯喹的组合 Download PDF

Info

Publication number
CN115701995A
CN115701995A CN202180040836.2A CN202180040836A CN115701995A CN 115701995 A CN115701995 A CN 115701995A CN 202180040836 A CN202180040836 A CN 202180040836A CN 115701995 A CN115701995 A CN 115701995A
Authority
CN
China
Prior art keywords
compound
prednisolone
hydroxychloroquine
therapeutically effective
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180040836.2A
Other languages
English (en)
Chinese (zh)
Inventor
G·L·希文
S·杜赫冈卡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN115701995A publication Critical patent/CN115701995A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180040836.2A 2020-06-11 2021-06-10 用于治疗皮肤红斑狼疮的tlr7抑制剂与泼尼松龙或羟氯喹的组合 Pending CN115701995A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202011024586 2020-06-11
IN202011024586 2020-06-11
PCT/US2021/036740 WO2021252718A1 (en) 2020-06-11 2021-06-10 Tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus

Publications (1)

Publication Number Publication Date
CN115701995A true CN115701995A (zh) 2023-02-14

Family

ID=76959055

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180040836.2A Pending CN115701995A (zh) 2020-06-11 2021-06-10 用于治疗皮肤红斑狼疮的tlr7抑制剂与泼尼松龙或羟氯喹的组合

Country Status (11)

Country Link
US (1) US20230310408A1 (https=)
EP (1) EP4164639A1 (https=)
JP (2) JP7751597B2 (https=)
KR (1) KR20230023717A (https=)
CN (1) CN115701995A (https=)
AU (1) AU2021286582A1 (https=)
BR (1) BR112022024999A2 (https=)
CA (1) CA3181964A1 (https=)
IL (1) IL298667A (https=)
MX (1) MX2022015760A (https=)
WO (1) WO2021252718A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230171469A (ko) 2021-04-16 2023-12-20 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
AU2024356361A1 (en) * 2023-10-02 2026-04-02 Bristol-Myers Squibb Company A method of treating lupus
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203815A1 (en) * 2010-06-16 2013-05-02 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
CN103153346A (zh) * 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 使用tlr7和/或tlr9抑制剂的治疗方法
WO2015200094A1 (en) * 2014-06-20 2015-12-30 Baylor Research Institute Methods and compositions for systemic lupus erythematosus (sle) therapy
US20180000790A1 (en) * 2016-06-29 2018-01-04 Bristol-Myers Squibb Company [1,2,4]TRIAZOLO[1,5-a]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270707A1 (en) 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203815A1 (en) * 2010-06-16 2013-05-02 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
CN103153346A (zh) * 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 使用tlr7和/或tlr9抑制剂的治疗方法
WO2015200094A1 (en) * 2014-06-20 2015-12-30 Baylor Research Institute Methods and compositions for systemic lupus erythematosus (sle) therapy
US20180000790A1 (en) * 2016-06-29 2018-01-04 Bristol-Myers Squibb Company [1,2,4]TRIAZOLO[1,5-a]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
朱铁山;方凯;: "亚急性皮肤型红斑狼疮23例临床分析", 中国医药导报, no. 11, 15 April 2016 (2016-04-15) *

Also Published As

Publication number Publication date
US20230310408A1 (en) 2023-10-05
JP7751597B2 (ja) 2025-10-08
BR112022024999A2 (pt) 2022-12-27
KR20230023717A (ko) 2023-02-17
WO2021252718A1 (en) 2021-12-16
EP4164639A1 (en) 2023-04-19
AU2021286582A1 (en) 2023-02-09
MX2022015760A (es) 2023-01-19
JP2025183420A (ja) 2025-12-16
JP2023530264A (ja) 2023-07-14
CA3181964A1 (en) 2021-12-16
IL298667A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
CN115701995A (zh) 用于治疗皮肤红斑狼疮的tlr7抑制剂与泼尼松龙或羟氯喹的组合
US11291659B2 (en) P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP6688224B2 (ja) Ｍｄｍ２を阻害する手段の投与による関節における変形性関節症の処置
ES2476368T3 (es) Tratamiento de la artritis reumatoide con una combinación de laquinimod y metotrexato
US12083129B2 (en) Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant
US20240033266A1 (en) Combination therapy involving diaryl macrocyclic compounds
US10537560B2 (en) P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US20190290652A1 (en) Method for treatment of solid malignancies including advanced or metastatic solid malignancies
CN120417891A (zh) Irak4降解剂及其用途
US20060083714A1 (en) Combination of a pde iv inhibitor and a tnf-alpha antagonist
KR20240055038A (ko) 다발성 경화증 치료를 위한 lou064
CN121001748A (zh) 可编程dna蛋白水解靶嵌合体及其使用方法
US20230310409A1 (en) Treating rheumatoid arthritis
WO2021207598A1 (en) Combination treatment with an agonist of p53 and a second therapeutic agent
JP2024525515A (ja) がんの予防用又は治療用の医薬組成物
WO2009019473A1 (en) Treatments for inflammatory arthritis
US20230019602A1 (en) Methods for treatment of motor neuron diseases
EA048070B1 (ru) Способы лечения кожной красной волчанки
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
CN118019540A (zh) 用于治疗多发性硬化的lou064
JP2026049047A (ja) 変形性膝関節症および肩関節周囲炎の疼痛改善剤
AU2024210360A1 (en) Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination